Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Clinical insights
Key research benefits
An FDA-approved (Sept. 2025, Forzinity) mitochondria-targeted peptide — the first of its kind approved for any indication, with the broadest human trial base of any longevity peptide here.
- 96-meter improvement in the 6-minute walk test and ~45% improvement in leg strength and heart function over a 168-week trial.
- Reduces oxidative stress at the source, cutting electron leakage and ROS production by roughly 40–60%.
- Restores mitochondrial structure (cristae) in aged tissue without needing to build new mitochondria.
Research backing
TAZPOWER trial (Barth syndrome, FDA approval basis); 18 human trials total — the most human evidence of any mitochondria-targeted peptide. Approved clinical dose (40mg/day) is far higher than typical wellness-use doses (1–2mg/day).
Research Grade Formula
SS31
Longevity & Anti-Aging
SS31 · 10mg
$75
Express Shipping $20 — Australia only
- Third-party tested
- Non-GMO
- GMP certified
How to use
Follow research handling and reconstitution guidance for this compound. Always use appropriate lab technique and sterile materials.
Research Dosage ProtocolWhat's inside
This vial holds SS-31 (elamipretide), a compact mitochondria-directed tetrapeptide prepared as a stable lyophilized powder for bench research on cellular energy systems.
Technical overview
- Contents: SS-31 research peptide, 10 mg per vial
- Sequence class: Szeto–Schiller aromatic-cationic tetrapeptide
- Approx. molecular weight: ~640 g/mol
- Purity: ≥99% (HPLC-verified; COA available per batch)
- Appearance: White to off-white freeze-dried solid
- Solubility: Mixes readily in aqueous research diluents
Reconstitute with bacteriostatic water at room temperature. For laboratory research and educational use only — not for human consumption.
Customer reviews
4.9
Based on 312 reviews
